Orexo has signed an exclusive worldwide licensing agreement with a Novartis affiliate to develop and commercialize a new product related to Orexo’s OX17 program. OX17, a combination of an H2-receptor blocker and a proton-pump inhibitor, is being studied for gastroesophageal reflux disease (GERD). Novartis will fund future development of the new product and will receive an exclusive license to all related intellectual property. Orexo will receive development milestone payments and will be elig...